Replies to post #3454 on Galectin Therapeutics Inc. (GALT)

[Amatuer17]

Not sure if this is complement or sarcasm.

I liked GALT but lost money after last trial results but the cancer focus I am more positive - the timeline is really short - we will see some movement - good or bad in next 2-3 months. I am expecting some very good results on Cohort 3 which may give a multi bagger (look at ARWR - P1 early trial results and market cap is $1.3 B and same with IMMU)
If cohort 3 results are in line with cohort 2 - we should see similar jump in price as ARWR

On CYDY - I am positive long term - like 2 years - I believe if they start 1st cancer trial - they will move up and I am very positive on CCR5 MoA and safety and Dr Pestell addition.
However the bloated share count will not give the multiplier that GALT can give

[Amatuer17]

Not sure if this is complement or sarcasm.

I liked GALT but lost money after last trial results but the cancer focus I am more positive - the timeline is really short - we will see some movement - good or bad in next 2-3 months. I am expecting some very good results on Cohort 3 which may give a multi bagger (look at ARWR - P1 early trial results and market cap is $1.3 B and same with IMMU)
If cohort 3 results are in line with cohort 2 - we should see similar jump in price as ARWR

On CYDY - I am positive long term - like 2 years - I believe if they start 1st cancer trial - they will move up and I am very positive on CCR5 MoA and safety and Dr Pestell addition.
However the bloated share count will not give the multiplier that GALT can give

[Amatuer17]

I

[Amatuer17]

Not sure if this is complement or sarcasm.

I liked GALT but lost money after last trial results but the cancer focus I am more positive - the timeline is really short - we will see some movement - good or bad in next 2-3 months. I am expecting some very good results on Cohort 3 which may give a multi bagger (look at ARWR - P1 early trial results and market cap is $1.3 B and same with IMMU)
If cohort 3 results are in line with cohort 2 - we should see similar jump in price as ARWR

On CYDY - I am positive long term - like 2 years - I believe if they start 1st cancer trial - they will move up and I am very positive on CCR5 MoA and safety and Dr Pestell addition.
However the bloated share count will not give the multiplier that GALT can give